Oncology: Prostate Cancer

Showing posts with label Prostate Cancer. Show all posts

April 15, 2007

Call For Better Prostate Cancer Biopsies

Routine collection of additional information from prostate cancer biopsies could allow better decisions about the best choice of treatment, according to a study published in the journal Cancer*.

Through a systematic review of the published evidence, scientists funded by the NHS Cancer Screening Programme, Cancer Research UK and Cancer Research Wales found evidence of a link between the spread of cancer to nerves in the prostate gland - called 'perineural invasion' or PNI - and a poorer outlook for prostate cancer patients.

The clinical significance of PNI has been unclear, and therefore current guidelines for pathologists make no mention of PNI, leaving it up to individual doctors to decide whether they check for it or not.

This review shows a significant association between PNI and the risk of disease recurrence but the risk associated with PNI remains impossible to fully quantify from the few studies that have been done so far. The researchers are recommending to the Royal College of Pathologists that PNI should be assessed in every case of prostate cancer. This would help determine more precisely the size of the associated risk and so aid future decisions about treatment.

Prostate cancer is the most common cancer in men, with more than 32,000 cases diagnosed each year in the UK, but the best approach to treatment is not always clear. Doctors currently have very little evidence to rely on when deciding on the most appropriate treatment option.

Widespread use in the US of the PSA (Prostate-Specific Antigen) test to identify asymptomatic prostate cancer has led to an increase in the number of prostate tumours detected, but the PSA test gives only limited information regarding a patient's prognosis.

The best management of early diagnosed tumours is particularly hard to judge. Options include radical prostatectomy - surgical removal of the prostate - and active surveillance or so-called 'watchful waiting', which may be chosen on the basis that most prostate tumours are slow-growing and occur in elderly men in whom prostate cancer will not be their cause of death. If, however, the cancer turns out to be growing faster, then active treatment is offered.

Cancer Research UK's Dr Patricia Harnden, lead author of the report, said: "We've shown that PNI increases the risk of recurrence in prostate cancer. If it is found in a prostate biopsy, it could mean the difference between choosing 'watchful waiting' and immediately treating the cancer, or perhaps giving a longer course of therapy. Pathology is not being used to its full potential in prostate cancer if PNI is not looked for.

" Making PNI a mandatory reporting item in the guidelines of the Royal College of Pathologists would have two effects - it would help gather more data on the exact association between PNI and risk of recurrence, and it would enable doctors to make more informed decisions on how best to treat their patients. We must also ensure that future studies of pathological prognostic factors such as PNI are designed well enough to properly assess their significance."

Julietta Patnick, director of NHS Cancer Screening Programmes, said: "I am very pleased that the NHS Cancer Screening Programmes has been able to facilitate this significant work. The results of this review will assist health professionals in making the best treatment decisions for patients."

Professor John Toy, medical director of Cancer Research UK, said: "Some prostate cancer patients have normal PSA levels, and some healthy men have high PSA levels that are not caused by cancer. It can often be extremely difficult to predict with certainty the prognosis for many men with early prostate cancer.

"Therefore, the identification of a prognostic marker that indicates an aggressive cancer would be of great value. PNI in a prostate biopsy may be such a marker. We must ensure that no opportunity to gather potentially important information about prostate cancer is wasted."

Professor Adrian Newland, president of the Royal College of Pathologists, said: "The Royal College of Pathologists welcomes this systematic review of PNI in prostatic cancer biopsies, particularly the identification of PNI as a reliable predictor of adverse clinical outcome.

"Detailed histological evaluation by medically-trained histopathologists is essential in the assessment of cancer specimens, particularly the identification of features of clinical value to patients and their supervising clinicians alike. The Royal College of Pathologists endorses the view expressed in the paper that well designed studies using pre-defined stringent protocols are now required to provide robust objective estimates of risk, following identification of PNI in prostatic core biopsies, as an aid in the planning of treatment for men diagnosed with prostate cancer."

* Harnden et al. (2007) "The prognostic significance of perineural invasion in prostatic cancer biopsies: A systematic review" CANCER; Vol. 109 Issue 1, pp13-24

For more statistics on prostate cancer, please visit Cancer Research UK's CancerStats website.

The NHS Prostate Cancer Risk Management programme

-- Information on Prostate Cancer Risk Management, prostate cancer and the PSA test is available here.

-- For more information about the NHS Cancer Screening Programmes, contact Andrea Whitfield, Caroline Greenaway, Sarah Gibbs or Helen Ketton in the press office on 020 7025 7510 or email screening@westminster.com

About Cancer Research UK

Together with its partners and supporters, Cancer Research UK's vision is to beat cancer.

-- Cancer Research UK carries out world-class research to improve understanding of the disease and find out how to prevent, diagnose and treat different kinds of cancer.

-- Cancer Research UK ensures that its findings are used to improve the lives of all cancer patients.

-- Cancer Research UK helps people to understand cancer, the progress that is being made and the choices each person can make.

-- Cancer Research UK works in partnership with others to achieve the greatest impact in the global fight against cancer.

http://www.cancerresearchuk.org

March 7, 2007

Call For Better Prostate Cancer Biopsies

March 5, 2007

Dendreon's PROVENGE Granted FDA Priority Review For The Treatment Of Asymptomatic, Metastatic, Androgen-Independent Prostate Cancer

Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and has assigned priority review status to the Company's Biologics License Application (BLA) for PROVENGE(R) (sipuleucel-T), its investigational active cellular immunotherapy for the treatment of asymptomatic, metastatic, androgen-independent (also known as hormone refractory) prostate cancer.

Priority Review is granted to products that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention of a serious or life-threatening disease. The goal for reviewing a product with Priority Review status is six months from the filing date. The Prescription Drug User Fee Act (PDUFA) date for completion of review by the FDA of the PROVENGE BLA is May 15, 2007.

"Clinical trials have shown that PROVENGE increases survival and is generally well tolerated in men with late-stage prostate cancer, a highly prevalent disease for which there are currently few available treatment options," said Mitchell H. Gold, president and chief executive officer of Dendreon. "We are extremely pleased the FDA has granted priority review to PROVENGE, which may represent an important new treatment option for men suffering from prostate cancer."

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than one million men in the United States have prostate cancer, with an estimated 232,000 new cases of prostate cancer diagnosed each year. More than 30,000 men die each year of the disease.

The BLA submission is based primarily on an improvement in overall survival observed in Study D9901, a multi-center, randomized, double-blind, placebo-controlled Phase 3 Study, the results of which were published in the July issue of the Journal of Clinical Oncology.

About PROVENGE

PROVENGE (sipuleucel-T) is an investigational product that may represent the first in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to stimulate a patient's own immune system. PROVENGE is in late-stage clinical development for the treatment of patients with advanced prostate cancer. In clinical studies, patients typically received three infusions over a one-month period as a complete course of therapy.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has headquarters in Seattle and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of a clinical trial for PROVENGE will not support an application for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov.

Dendreon Corporation
http://www.dendreon.com

March 4, 2007

Panacea Pharmaceuticals Initiates Pivotal, Prospective Multi-Center Study To Evaluate The Diagnostic Performance Of PC Detect(SM) For Prostate Cancer

Panacea Pharmaceuticals, Inc. announced the initiation of the pivotal, prospective multi-center clinical study to evaluate the diagnostic performance of PC Detect(SM), the Company's prostate cancer screening test. Patients are currently being enrolled in this study at 15 sites in the U.S. to demonstrate that the performance of PC Detect(SM), a simple blood test, will serve as an aid in the detection of prostate cancer in men 50 years and older who are referred for biopsy because of a tPSA > 4.0 ng/mL and/or an abnormal digital rectal exam. The addition of PC Detect(SM) to the current screening methods should reduce the number of men recommended to undergo prostate biopsies and subsequently found to be cancer- free. PC Detect(SM) will soon be available from Panacea Laboratories (http://www.panacea-labs.com), a division of Panacea Pharmaceuticals, which is fully compliant with the requirements of the Clinical Laboratory Improvement Amendments of 1988 (CLIA). The Company anticipates submission of a Pre-Market Application (PMA) to the U.S. Food and Drug Administration later in 2007 to facilitate development of a PC Detect(SM) kit, which will be commercialized through clinical laboratories around the country.

Prostate cancer is currently the most prevalent form of cancer in men and the second leading cause of male cancer death in the United States. The major screening tools for prostate cancer used by physicians to determine whether to refer a patient for a prostate biopsy are the prostate-specific antigen (PSA) and the digital rectal examination (DRE). The American Cancer Society (ACS) recommends a PSA blood test and DRE yearly, beginning at age 50. However, some controversy exists as to the utility and predictive validity of PSA for prostate cancer. PSA is a tissue-specific protein and has been shown to be elevated in both benign prostate conditions as well as prostate cancer. According to the ACS, patients with a PSA > 10 ng/mL are recommended to have a biopsy since >50% of these men have been found to have biopsies positive for cancer. A biopsy may be recommended for a non-suspicious DRE result and a PSA result of between 4-10 ng/mL as 25% of these men will also be positive for prostate cancer. DRE has a reported sensitivity of 55%-68% in asymptomatic men, but values as low as 18%-22% have been reported. The reported positive predictive value of DRE is 6%-33%. A cutoff value of a PSA 4.0 ng/mL at base- line has been found to have a sensitivity of 46% with respect to the identification of cases of prostate cancer that would occur within the next 10 years. The reported positive predictive value of PSA in asymptomatic men is 28%-35%.

PC Detect(SM), a CLIA laboratory service, is a new method for screening a patient's serum with a simple blood draw to help determine the likelihood that prostate cancer is present. PC Detect(SM) is recommended for men who have an elevated PSA and/or an abnormal DRE. PC Detect(SM) provides information to differentiate prostate cancer from benign conditions, and to help guide both the physician and patient regarding further diagnostic testing and management. Human Aspartyl (Asparaginyl) Beta-Hydroxylase (HAAH) is a cancer biomarker. HAAH has been established as an excellent biomarker for many cancer diagnoses based upon its biochemical/cellular properties and its known biological function. The protein is undetectable in sera from cancer-free individuals; thus, an elevated serum protein level of HAAH is highly diagnostic for cancer. Low/undetectable levels of HAAH, when measured with PC Detect(SM), may obviate the need for a prostate biopsy, despite a slightly elevated PSA. Thereby, a patient could avoid an unnecessary biopsy with its associated morbidity and cost.

"PC Detect(SM), in combination with PSA and DRE, should significantly enhance our ability to identify men with a high likelihood of having prostate cancer as compared to screening with PSA and DRE alone," commented Neal Shore, MD, of the Carolina Urologic Research Center and Grand Strand Urology, Myrtle Beach, South Carolina, who serves as Principal Investigator for the study. "As a practicing urologist, I look forward to using PC Detect(SM) to enhance the quality of care for my patients and reduce the number of unnecessary prostate biopsies."

"Initiation of the pivotal PC Detect(SM) marks a significant milestone for Panacea. This test should improve the physician's ability to identify men with a high likelihood of having prostate cancer, and avoid biopsies for those with a negligible risk of cancer," observed Stephen N. Keith, MD, MSPH, President and Chief Operating Officer at Panacea. "The addition of PC Detect(SM) to the list of diagnostic tests offered by Panacea Laboratories; and the FDA approval of this test and subsequent development of a kit, provide further evidence that Panacea is a leading research, product development and commercial life science company."

About Panacea's Oncology Platform

Panacea is pursuing the development of antibodies directed against human aspartyl (asparaginyl) beta-hydroxylase (HAAH) as novel agents for the treatment of cancer with liver cancer as its first intended indication. The Company is exploring both naked anti-HAAH antibodies as well as HAAH antibodies conjugated to chemotherapeutic agents. Panacea is also pursuing the development of diagnostic products based on HAAH gene expression and anti- HAAH antibodies. A test to determine responsiveness to a current therapy of choice in patients with chronic myelogenous leukemia utilizing HAAH gene expression is available through Panacea Laboratories. A proprietary blood- based assay has shown high sensitivity and specificity in the detection of a range of cancers, thus facilitating the diagnosis and therapeutic management of disease. Initial targets for the blood-based diagnostic products include prostate and liver cancers.

About Panacea Pharmaceuticals, Inc.

Panacea Pharmaceuticals, Inc. is a privately-held biopharmaceutical company focused on the development and commercialization of therapeutics and diagnostics for diseases with substantial, unmet clinical needs. The Company's product development strategy is based on novel therapeutic agents and approaches for cancer treatment, as well as acute and chronic neurodegenerative conditions, such as hypoxia-induced neurological insult, Parkinson's Disease, and Alzheimer's Disease. Panacea has an extensive patent portfolio covering its neurodegenerative and oncology technologies. Panacea Laboratories is a division of Panacea Pharmaceuticals, Inc.

More information about the Company is available at http://www.PanaceaPharma.com.

Except for historical information presented in this press release, matters discussed herein may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements are based on the opinions and estimates of management only as of the date of this release and are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance, or achievements expressed or implied by such statements. Factors that might cause such a difference include, but are not limited to, uncertainties related to our access to capital, the progress, costs, and results of any clinical trials undertaken by us, progress of our research and development projects, and uncertainties related to whether our product candidates would ultimately achieve commercial success. We do not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise unless required by law.

Panacea Pharmaceuticals, Inc.
http://www.panaceapharma.com

US Cancer Deaths Fall Second Year In A Row Despite Growing And Aging Population

The American Cancer Society has reported that the number of cancer deaths in the US has fallen slightly again, the second year in a row.

About 3,000 fewer people died from cancer between 2003 and 2004 compared with the previous year. This is small compared to the total annual death toll of more than 500,000, but it could signify the start of a most welcome reversal.

Cancer death rates (as opposed to total deaths, this is the number of deaths per 100,000 people) in the US have been declining steadily for years and the latest report by the American Cancer Society shows that the decline has been sharper in the last reported year, 2004. And the decline is actually more significant because it has outpaced the growth in the population, and despite the fact it is getting older.

Tobacco control is thought to be the biggest reason for the decline, because of the impact on reduction of cases of lung cancer, expecially in men. The second reason is the gradual improvements in treatment and early detection of cancers, as with the increased use of colonoscopies, and breast screening, for example.

According to the chart published in the report, one can see the large reduction in the rate of lung and bronchial cancer in men, where it rose steadily from 1930, peaked at around 90 cases per 100,000 of the male population in 1990 and reduced again steadily toward a present day figure of around 75 cases per 100,000.

Stomach cancer in men shows a steady decline from above 40 cases per 100,000 in 1930 to below 10 in 2003.

Colon and rectal cancer in men are also steadily dropping, while liver cancer is staying about the same, with a slight increase over the last decade. Prostate cancer rose steadily and peaked in 1990 to around 40 cases per 100,000 and is now approaching the 1930 figure of around 20-25 per 100,000.

The only male cancers to have risen, albeit very slightly, in incidence are pancreatic cancer and leukaemia, showing a rate of around 10 to 12 cases per 100,000 of the male population.

The figures for female cancers since 1930 have followed a broadly similar pattern as the male, with the lung and bronchial rates not yet coming down but they appear to have settled around the much lower rate of 40 per 100,000 cases.

Breast cancer rates hovered at around 30 cases per 100,000 females until around 1990 when they started coming down to the 2003 rate of about 25 cases per 100,000.

Stomach, uterus, colon and rectal cancer rates in women have steadily declined and at 2003 were at under 10 cases per 100,000. As for the men, pancreatic cancer has not reduced and is around 10 per 100,000, while ovarian cancer has also stayed steady at around 10 cases per 100,000 women.

The NCS estimates that the number of Americans alive today who have or have ever had cancer is about 10.5 million (roughly 4 per cent, or 1 in 25 of the population). Some of them don't have it any more, while others may still be having treatment.

At least half of all new cancer cases are cancers that can be prevented or detected earlier and people who get them have an 86 per cent chance of surviving five years or more. This high survival rate is due to improved, earlier screening as well as reduction in deaths.

The NCS suggests that in 2007, the number of new cancer cases in America will be about 1,444,920, excluding certain types such as most of the non-invasive and the basal and squamous cell skin cancers. The numbers of these last two is expected to be around 1 million this year.

The number of people in America who will die of cancer in 2007 is likely to be around 559,650, or more than 1,500 per day.

In the US, cancer is the second biggest killer after heart disease and accounts for about 1 in every 4 deaths.

The percentage of Americans who survived cancer for five or more years after being diagnosed between 1996 and 2006 is 66 per cent. This is a significantly improved survival rate compared with 30 years ago when it was 51 per cent. The ACS point out that while this figure is useful for making statistical comparisons on effectiveness of treatment and diagnosis, it is not useful in individual cases, nor is it a measure of long term survival rate since deaths from cancer can occur after the five years.

The report states that childhood cancer is rare, and that the mortality rates for childhood cancers (up to age 14) have come down by 48 per cent since 1975. The ACS estimates that 10,400 cases of childhood cancer will be diagnosed in 2007, and 1,545 American children will die of cancer in 2007, mostly from leukaemia.

The four cancers likely to be the biggest killers in 2007 will be: lung cancer, prostate cancer, breast cancer and colon cancer.

American Cancer Society Statistics for 2007.

Written by: Catharine Paddock
Writer: Medical News Today

Sunshine Pill For Prostate Cancer In 2009?

A tablet designed to emulate the healing power of the sun could be available for the treatment of advanced prostate cancer as early as 2009. But it remains to be seen whether the drug will be the revolution in prostate cancer care that its makers claim.

The drug, Asentar (DN-101), is based on vitamin D and is given to patients in the advanced stages of prostate cancer along with chemotherapy drugs. Drug makers came up with the idea because vitamin D from sunlight improves the prognosis of certain cancers. But taking natural levels of the vitamin has no effect. Novacea, the company that makes Asentar, produced a novel formulation that reproduces the healing effect without the dangerous side-effects of a vitamin D overdose. If the on-going phase III trial goes to plan, the new drug should be available in 2009, reports Chemistry & Industry, the magazine of the SCI.

'If the results of the phase III trial are as good as those of the phase II trial, that would be significant,' says Nick James, professor of oncology at the University of Birmingham. In the phase II trials, Asentar significantly improved survival rates, 9 months over patients taking chemotherapy drugs (taxotere) alone. 'On average, patients in the advanced stage of the disease survive about 18 months, so an extension of 9 months would be very significant in my view,' says James.

Asentar provides levels of vitamin D 50-100 times higher than normal. Patients would be expected to take one tablet once a week with their weekly regime of taxotere for three weeks out of every four.

Business analysts say Asentar is a potential blockbuster, because prostate cancer rates are expected to soar in the next few years. But James is not so sure. 'A confounding factor is that if you go looking for more cases of cancer, you will find them. But this does not give you an accurate estimate of how many people will go on to develop advanced disease. In fact death rates are going down, which means that the market for this drug is probably pretty static.'

James also points out that it is far from certain that the Phase III trials will repeat the success of early trials. 'The phase II trial used a less than optimal taxotere regime so the survival rate may have been artificially inflated,' he says. He points out, however, that it may be that the Asentar will eventually prove applicable in the earlier stages of the disease.

Prostate cancer is the second leading cause of cancer death in men. Prostate cancer kills one man every hour in the UK.

###

Chemistry & Industry

Please acknowledge Chemistry & Industry as the source of these items. If publishing online, please include a hyperlink to http://www.chemind.org/ Please note Chemistry & Industry uses '&' in its title, please do not correct to 'and'.

About Chemistry & Industry

Chemistry & Industry magazine from SCI delivers news and comment from the interface between science and business. As well as covering industry and science, it focuses on developments that will be of significant commercial interest in five- to ten-years time. Published twice-monthly and free to SCI Members, it also carries authoritative features and reviews. Opinion-formers worldwide respect Chemistry & Industry for its independent insight.

About SCI

SCI is a unique international forum where science meets business on independent, impartial ground. Anyone can join, and the Society offers a chance to share information between sectors as diverse as food and agriculture, pharmaceuticals, biotechnology, environmental science and safety. As well as publishing new research and running events, SCI has a growing database of member specialists who can give background information on a wide range of scientific issues. Originally established in 1881, SCI is a registered charity with members in over 70 countries.

Contact: SCI Press Office
Society of Chemical Industry

M. D. Anderson Announces Collaboration With The National Cancer Institute Of Mexico

Building on a relationship that spans more than three decades, The University of Texas M. D. Anderson Cancer Center in Houston and Instituto Nacional de CancerologГa (INCAN) in Mexico City (the National Cancer Institute of Mexico) have announced a formal agreement to expand opportunities for collaboration in clinical cancer research, prevention and education.

The agreement between M. D. Anderson and INCAN is based on their mutual commitment to research-driven patient care in a setting of academic excellence, and represents a step forward in the global fight against cancer. As the leading institution and governing body for cancer policy, treatment, education and research in Mexico, INCAN shares M. D. Anderson's strong interest in advancing programs in cancer prevention and translational medicine.

Leaders and representatives from both institutions participated in a signing ceremony at INCAN that coincided with the 60th anniversary of its founding and a symposium on leukemia. The institutions agree that leukemia, along with breast cancer and epidemiological studies, will be initial focus areas for collaboration. It is anticipated that the relationship between the two institutions will further advance multidisciplinary, patient care programs throughout INCAN's network of 24 national cancer centers and lead to a greater understanding of cancer in Mexican and Mexican-American populations.

"For more than 30 years, INCAN has been a valuable partner to M. D. Anderson, and patients in Mexico and the United States have benefited from our shared knowledge," said John Mendelsohn, M.D., president of M. D. Anderson. "This agreement formalizes a program to continue the important work we have accomplished together and advances our efforts to eradicate cancer throughout the world."

M. D. Anderson's long-standing relationship with INCAN has developed in part because of the geographic proximity of the centers, as well as the close historical, cultural and socioeconomic ties between Mexico and Houston. Specifically, the agreement will further shared population-based studies to understand the risk factors for development of certain cancers among Mexicans and Mexican-Americans, including the Mexican-American Cohort Study, the largest study ever to focus entirely on the health needs of Mexican-American families, currently underway at M. D. Anderson. Additionally, the collaboration establishes a plan for a national Mexican tissue bank, and faculty training and education activities related to breast cancer and leukemia, eventually expanding to include clinical research and translational projects.

Breast cancer is the second most common cancer in Mexico and accounts for 10.6 percent of all cancers and 16.4 percent of cancers in women. Mortality rates from breast cancer in Mexico have increased over the past 10 years and are expected to continue to rise as a significant portion of the population in Mexico ages.(1) Prostate cancer is the most common cancer in men with more than 19 new cases per 100,000 diagnosed each year.(2)

"As a nation, Mexico recognizes the devastating effects of cancer and is dedicated to providing the best cancer care for the people of Mexico," said Alejandro Mohar, M.D., the General Director of INCAN. "Our expanded relationship with M. D. Anderson ensures that communities throughout Mexico will have access to the latest advances in cancer research and treatment."

Mohar attended the signing ceremony along with INCAN leader Alfonso DueГ±as, M.D., Ph.D., Director of Research, Dolores Gallardo, M.D., Director of Academic Affairs, and Abelardo Menesess, M.D., Medical Director. Several M. D. Anderson faculty members attended, including Stephen Tomasovic, Ph.D., Senior Vice President, Academic Affairs; Vicente Valero, M.D., Professor, Breast Medical Oncology; Jorge E. Cortes, M.D., Professor, Leukemia; Kendra Woods, Ph.D., Director, Extramural Programs; and Hilario E. Mata, Ph.D., Project Director of Extramural Programs.

"Many faculty members at M. D. Anderson have deep-rooted professional and personal interests in Mexico," said Tomasovic. "This agreement builds on their commitment to the prevention and management of cancer throughout the region, and continues to fulfill the mission of M. D. Anderson."

Among the first efforts emerging from the sister agreement is M. D. Anderson's participation in the XXIV Annual Congress of INCAN, planned for February 2007. The symposium will highlight achievements across several disciplines of oncology and will bring together faculty from both institutions to discuss projects in clinical, basic and translational research and training.

###

(1) Cancer, Vol. 91, No. 4, pp. 863-868, 2001

(2) GLOBOCAN, 2002.

M. D. Anderson Cancer Center

M. D. Anderson Cancer Center, an institution created by the Texas Legislature in 1941, has established an international reputation as one of the world's preeminent centers for cancer patient care, research, education and prevention. A multidisciplinary approach, and dedication to translational research, education and prevention are hallmarks of M. D. Anderson. Looking to the future, M. D. Anderson is increasingly focused on sharing new research developments and clinical expertise through affiliations with premier institutions around the world. M. D. Anderson was designated by the National Cancer Institute (NCI) as one of the first three Comprehensive Cancer Centers in the United States. Consistently ranked one of the top two cancer centers in the United States by U.S. News & World Report's "America's Best Hospitals" since the survey's inception, M. D. Anderson has provided care for more than 700,000 cancer patients since 1944 and 74,000 in the last year alone.

Instituto Nacional de CancerologГa

The Instituto Nacional de Cancerologia of Mexico (INCAN) is the leading institution and center for cancer treatment, education and research in Mexico. A decentralized department of the Secretary of Health in Mexico, INCAN serves as the country's primary reference and governing body for cancer care and policy. INCAN is dedicated to providing cancer care of the highest quality to patients, as well as establishing best practices in prevention, diagnosis and multidisciplinary treatment of cancer.

Contact: Julie Penne
University of Texas M. D. Anderson Cancer Center

March 2, 2007

Ciphergen Announces Issuance Of European Patent Covering A Method For Aiding Prostate Cancer Diagnosis

Ciphergen Biosystems, Inc. (Nasdaq: CIPH) today announced that the European Patient Office (EPO) has issued EU Patent No. 1 224 466, entitled "Prostate Cancer Marker Proteins," for aiding in prostate cancer diagnosis. The patent describes a method that measures certain protein biomarkers that are present in the blood of patients with prostate cancer versus patients who do not have prostate cancer.

"This patent is another example of Ciphergen's position as a leading developer of novel high-value diagnostic tests, and our intellectual property portfolio is growing in size and strength," said Gail S. Page, Chief Executive Officer of Ciphergen Biosystems. "We continue to generate promising data for biomarkers that may be useful for prostate cancer diagnosis, disease monitoring, or prediction of recurrence."

About Ciphergen's Prostate Cancer Development Program

Ciphergen has a diagnostic program in prostate cancer and is evaluating a panel of biomarkers as potential tests for prostate cancer diagnosis, progression and recurrence.

In May 2006, Ciphergen and Johns Hopkins reported the discovery of two biomarkers that, when combined with prostate-specific antigen (PSA), were highly predictive of likelihood of recurrence of prostate cancer. The data resulted from two studies -- one examining over 400 men with prostate cancer, and the other examining 50 pairs of men followed for five years with prostate cancer matched for age, cancer stage and other clinical parameters. These results suggest the potential for a test to 1) aid in the diagnosis of prostate cancer; 2) aid in the stratification of risk of highly aggressive prostate cancer, independent of other clinical variables; 3) reduce over-treatment of prostate cancer in cases not likely to be lethal and; 4) shift treatment to those cases that are particularly likely to be lethal.

Patent applications in the U.S. and Japan are pending. Inventors on this patent include Dr. Tai-Tung Yip, Senior Research Fellow at Ciphergen and inventor of the SELDI technology, and Christine Yip, Senior Scientist at Ciphergen.

About Ciphergen

Ciphergen Biosystems, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Ciphergen, along with its prestigious scientific collaborators, has ongoing diagnostic programs in oncology/hematology, cardiology and women's health with an initial focus in ovarian cancer. Based in Fremont, California, more information about Ciphergen can be found on the web at http://www.ciphergen.com/.

Safe Harbor Statement

This press release contains forward-looking statements. For purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"), Ciphergen disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such forward-looking statements include statements regarding the continued growth of our intellectual property portfolio and the efficacy and utility of our diagnostic tests for prostate cancer diagnosis, progression and recurrence. Actual results may differ materially from those projected in such forward-looking statements due to various factors, including the possibility that future development efforts may not proceed as anticipated. Investors should consult Ciphergen's filings with the Securities and Exchange Commission, including its Form 10-Q filed November 20, 2006, for further information regarding these and other risks related to the Company's business.

Ciphergen Biosystems, Inc.
http://www.ciphergen.com/

National Prostate Cancer Coalition Launches Clinical Trial Education Program

The National Prostate Cancer Coalition (NPCC), today announced the launch of "Get in the G.A.M.E. -- Get All Men Educated about Prostate Cancer Clinical Trials" to help men with prostate cancer understand that clinical trials may be an important option to consider. Talking with a doctor about clinical trials is particularly important for men with recurrent disease who are at risk for or already suffering from bone metastases (spread of cancer to the bone). Clinical trials advance science in the areas of disease they study and in some cases provide access to potential new therapies.

"We're conducting our "Get in the G.A.M.E. - Get All Men Educated" initiative because a recent survey of prostate cancer patients shows that only a very small percentage of patients -- about 12 percent of men with prostate cancer -- know that clinical trials are an option," said NPCC CEO Richard N. Atkins, M.D. "Clinical trials examine the safety and benefit of experimental drugs to find new treatments for prostate cancer aimed at extending and improving quality of life and ultimately a cure. It's important for men to ask their urologist or oncologist about trials that may be helpful."

Prostate cancer is the most commonly diagnosed cancer in America among men with more than 218,000 new cases expected to be diagnosed in 2007. Approximately one man in six men is diagnosed with prostate cancer in his lifetime and all men with prostate cancer are at risk to develop bone metastases.

"Being informed of clinical trials is particularly important for men with recurring prostate cancer for whom fewer approved therapies exist," said Atkins. "In fact, certain cancers are more likely to spread to the bone than others and prostate cancer is one of them."

The survey, "Cancer Clinical Trials Awareness and Attitudes in Cancer Survivors," conducted by the Coalition of Cancer Cooperative Groups and Northwestern University polled nearly 2,000 U.S. cancer survivors, and found that as few as one in 10 cancer survivors report ever being made aware of trial opportunities during treatment. For those patients who reported participating in clinical trials, the survey found that 92 percent of participants had a positive experience with their clinical trial.

"This survey tells us that we need to do a better job of informing men about clinical trials that may make a difference in how their disease is managed in helping determine the potential benefit of new agents," said Matthew Smith, M.D., PhD assistant physician, division of hematology/oncology, Massachusetts General Hospital, Boston, Mass. "We are currently conducting clinical trials to evaluate the potential for an investigational therapy to prevent and treat the bone metastases in men with prostate cancer."

"Education about, and when appropriate, participation in, clinical trials is so important -- that's why we are encouraging dialogue between men with prostate cancer, their families and their physicians," noted Atkins.

To learn more about prostate cancer or bone metastases go to http://www.fightprostatecancer.org. For information about relevant clinical trials, go to http://www.rising-psa.com. Patients accessing this Web site and toll free number will be provided with information about Amgen and other available prostate cancer clinical trials.

About Bone Metastases

Bone metastases are cancer cells that separate from tumors, enter the bloodstream, and migrate to bone tissue where they settle and grow. The tumor cells and bone cells interact, which may lead to the disruption of normal bone metabolism and cause an increase in osteoclast (cells responsible for bone resorption) activity. This interaction may stimulate tumor growth and bone destruction.

Bone metastases are one of the most frequent causes of pain in people with cancer and may lead to severe skeletal complications, such as fractures, spinal cord compression resulting in paralysis, need for surgery to bone, and need for radiation to bone for pain palliation.

Approximately 452,000 people in the United States suffer from cancer with metastases to the bone. Certain cancers, like prostate cancer, are more likely to spread to the bone than others.

About the National Prostate Cancer Coalition and Get in the G.A.M.E. Initiative

Celebrating 10 years of saving lives, the National Prostate Cancer Coalition sets the standard in rapidly reducing the burden of prostate cancer on men and their families through awareness, outreach and advocacy.

The Get in the G.A.M.E. Program has been made possible by financial support from Amgen, Inc.

National Prostate Cancer Coalition
http://www.fightprostatecancer.org

Swedish Cancer Institute First In The World To Offer GPS For The Body(R) To Assist With Precision-Guided Prostate Cancer Treatments

Swedish Cancer Institute today announced it is the first cancer-care program in the world to provide prostate cancer patients commercial access to the Calypso(R) 4D Localization System for precision-guided radiation therapy delivery to the prostate with continuous, objective, organ-motion tracking accuracy.

Radiation therapy is used to treat about one million cancer patients in the United States each year and is very effective in destroying cancer cells. However, in prostate cancer treatment the most common side effects arise when the radiation beam misses the prostate but irradiates adjacent healthy organs causing complications like impotence, urinary incontinence and rectal bleeding. Therefore, doctors must guard against damaging healthy tissues that surround the tumor caused by misalignment and unpredictable tumor motion.

The Calypso(R) 4D Localization System is now enabling Swedish Cancer Institute physicians the ability to pinpoint a prostate tumor's location with greater accuracy and continuously monitor its position in a real-time fashion during radiation treatment. This technology, which has FDA 510(k) clearance, uses tiny electromagnetic sensors, called Beacon(R) transponders, that are each about the size of a small grain of rice. Transponders are implanted in the prostate prior to treatment. Subsequently, the Calypso System continuously monitors the position and motion of the organ by tracking transponder positions during therapy delivery and alerts clinicians when the prostate is not properly aligned with the radiation beam.

"Patients are well educated in prostate cancer treatment options and seek the best treatment approach possible. We expect the Calypso(R) 4D Localization System to factor into the patient's decision when selecting Swedish for their radiation treatment. In fact, almost half of the initial patients implanted with Beacon(R) transponders have traveled more than 100 miles from their home to receive treatment at the Swedish Cancer Institute," said John Sylvester, M.D., radiation oncologist with the Seattle Prostate Institute at Swedish Medical Center. "That's quite a testimony to the value patients place on accurate treatment."

"This 4D monitoring technology is a key building block in the Swedish Cancer Institute's commitment to provide patients access to a complementary array of leading-edge radiation therapy delivery options through the Center for Advanced Targeted Radiation Therapies," said Albert B. Einstein Jr., M.D., executive director of the Swedish Cancer Institute. "We're honored to be the first program in the world to offer the Calypso System to prostate cancer patients."

The Swedish Cancer Institute's radiation oncology staff understood the importance of organ motion and its impact in radiation therapy delivery early on. That is why this collaborative relationship with fellow Seattle-based organization Calypso made sense and worked well.

"Over the last several years early product concepts were evaluated by Swedish Cancer Institute staff and contributed to the product design and operation," said Eric R. Meier, Calypso Medical president and CEO. "As a result, Calypso Medical was able to develop a very robust application, designed to improve the accuracy, efficiency and, for the first time, enable continuous, real-time tumor tracking. We believe this will pave the way for expanded treatment delivery options in radiation therapy and enable clinicians to better manage organ motion during therapy. By partnering with clinical experts at the Swedish Cancer Institute, we expect to see unprecedented advancements in radiation therapy management and expanded treatment delivery options."

Frazier Healthcare Ventures founded and significantly participated in every financing round involving Calypso Medical for the development of early technology concepts. "The Swedish Cancer Institute's appreciation for the importance of organ motion and its impact on radiation therapy delivery combined with Calypso Medical's technical expertise and funding from Frazier Healthcare enabled this collaborative relationship between fellow Seattle-based organizations to produce excellent results," said Trevor Moody, general partner with Frazier Healthcare Ventures.

About Calypso(R) Medical Technologies, Inc.

Calypso Medical Technologies, Inc. ("Calypso") is a Seattle-based, privately held medical device company. The company's proprietary tumor localization system utilizes miniaturized implanted devices (Beacon(R) electromagnetic transponders) to continuously, accurately and objectively pinpoint the location of tumors for improved accuracy in radiation therapy. Calypso addresses two major issues in modern radiation oncology: errors in treatment set-up and tumor motion during treatment. In addition, the Calypso(R) 4D Localization System's non-ionizing electromagnetic guidance has the potential to improve work flow efficiency and treatment-room utilization. The technology is designed for body-wide cancers commonly treated with radiation therapy, including prostate, breast, lung, head, neck and other radiation therapy target organs. FDA 510(k) clearance for use in the prostate only was received July 2006. For more information, visit http://www.calypsomedical.com.

About Swedish Medical Center

Swedish Medical Center is the largest, most comprehensive, nonprofit health provider in the Pacific Northwest. Founded in 1910, Swedish now encompasses three hospital campuses -- First Hill, Cherry Hill (formerly Providence) and Ballard -- totaling 1,245 licensed beds, a new freestanding emergency room and specialty center in Issaquah, Swedish Home Care Services and Swedish Physicians -- a network of 12 primary-care clinics located throughout the Greater Seattle area. In addition to general medical and surgical care, Swedish is known as a regional referral center, providing specialized treatment in areas such as cancer care, cardiovascular care, orthopedics, high-risk obstetrics, neurological care, sleep medicine, pediatrics, organ transplantation and clinical research. For more information, visit http://www.swedish.org.

About Swedish Cancer Institute

The Swedish Cancer Institute (SCI) opened in 1932 as the first dedicated cancer-care center west of the Mississippi. Today, it is the largest and most comprehensive cancer treatment program in the Pacific Northwest, caring for more people with more types of cancer than any other provider in the region. The Institute has a presence on all three of Swedish's hospital campuses -- First Hill, Cherry Hill (formerly Providence) and Ballard -- as well as in East King County via a new medical oncology clinic near Issaquah. A true multidisciplinary facility, the SCI offers a wide range of advanced cancer-treatment options in chemotherapy, radiation therapy and surgery -- backed by extensive diagnostic capabilities, patient education and support-group services. The SCI's clinical-research arm encompasses industry-sponsored and cooperative group therapeutic trials, cancer screening and prevention trials, and investigator-initiated trials. Breast-cancer screening and diagnostics are available through the Swedish Breast Care Centers and mobile mammography units. Swedish radiation therapy is also offered at area hospitals including Stevens Hospital (Edmonds); Valley Medical Center (Renton); Highline Community Hospital (Burien) and Northwest Hospital (North Seattle). For more information, visit http://www.swedish.org.

About the Center for Advanced Targeted Radiation Therapies

The Swedish Cancer Institute's Center for Advanced Targeted Radiation Therapies encompasses the comprehensive and complimentary array of advanced and emerging radiation delivery tools available to patients for both approved therapies and clinical research efforts. They include a variety of technologies, including Intensity-Modulated Radiation Therapy (IMRT), Image- Guided Radiation Therapy (IGRT), linear accelerator-based stereotactic radio surgery, Calypso(R) 4D Localization System, Xoft Axxent(TM) Electronic Brachytherapy System, MammoSite(R) Radiation Therapy System, the Seattle CyberKnife Center(TM) at Swedish Medical Center, and Northwest Hospital Gamma Knife Center.

About the Seattle Prostate Institute at Swedish Medical Center

The Seattle Prostate Institute was established in 1997 by a group of physicians who, in the mid-80's, had pioneered the introduction and development of ultrasound-guided prostate implantation in the United States from their base at Seattle's Northwest Hospital. After relocating to Swedish Medical Center, these physicians sought to expand and improve upon the work they had started with an emphasis on the highest standards of patient care, medical research, and clinical education. To date, SPI physicians -- who include Drs. John Blasko, Peter Grimm, John Sylvester and Stephen Eulau -- have performed more that 10,000 prostate implants. The leadership role and professional reputation of the SPI medical team has firmly established the Institute as the leading center of expertise in the area of prostate brachytherapy. Not only do patients come from around the nation and around the world for consultation and treatment, but physicians and other health professionals from the U.S. and abroad are also drawn to Seattle to participate in SPI's highly respected clinical education and training programs. For more information, visit http://www.seattleprostateinst.com.

About Frazier Healthcare Ventures

Founded in 1991, Frazier Healthcare is one of the nation's leading providers of venture capital and growth equity to emerging health-care companies. It has more than $1.2 billion of capital under management. Having invested in more than 100 emerging health-care organizations, Frazier Healthcare is well known for its depth of experience and the technical expertise of its investment team. This experience encompasses product development and launch, clinical trial implementation and design, industry operating experience, academic research and clinical practice. For more information, visit http://www.frazierhealthcare.com.

Swedish Cancer Institute
http://www.swedish.org/

February 26, 2007

Europe's Aging Population Causing Major Increase In Cancer Burden Experts Warn

Between 2004 and 2006, the number of new cases of cancer diagnosed each year in Europe has increased by 300,000 according to new estimates published in a report in Annals of Oncology [1]. It is estimated that in 2006 there were 3.2 million new cases of cancer (up from 2.9 million in 2004) and 1.7 million deaths from the disease in the whole of Europe.

Professor Peter Boyle, Director of the International Agency for Research on Cancer (IARC) in Lyon, France, who prepared the report with IARC colleagues, warned that despite better prevention and treatments, Europe faced a major increase in the cancer burden because of the ageing population. He said urgent action was needed now to tackle cancer, particularly in Central and Eastern Europe, through measures such as tobacco control and more widespread screening for breast and colorectal cancer, as well as efforts to improve people's diet and exercise and reduce levels of obesity.

"With an estimated 3.2 million new cases (53% occurring in men, 47% in women) and 1.7 million deaths (56% in men, 44% in women) each year, cancer remains an important public health problem in Europe, and the ageing of the European population will cause these numbers to continue to increase, even if age-specific rates of cancer remain constant," he said. "Evidence-based public health measures, such as screening, exist to reduce deaths from breast, cervical and colorectal cancer, while the incidence of lung cancer, and several other forms of cancer, could be diminished by tobacco control."

The 25 EU countries accounted for nearly 2.3 million of the new cases and over one million cancer deaths [2].

Lung, colorectal, breast and stomach cancers are the top four killers

Lung cancer remains the biggest killer, with an estimated 334,800 deaths in 2006 (19.7% of the total number of deaths from cancer), followed by colorectal cancer (207,400 deaths), breast cancer (131,900 deaths) and stomach cancer (118,200 deaths).

"Lung cancer retains its status as the leading cause of cancer death in Europe in 2006," said Prof Boyle. "The overwhelming majority of lung cancer is caused by tobacco smoking, and tobacco control is clearly a number one priority in Europe, not only aimed at men, particularly the male populations of Central and Eastern Europe, but increasingly targeted towards women, especially in Northern Europe."

Breast, colorectal and lung cancers have the highest incidence

Since the previous estimates for 2004, breast cancer has overtaken lung cancer as the commonest cancer to be diagnosed overall, with 429,900 new cases in 2006 (13.5% of all cancer cases). It was followed by colorectal cancer (412,900 cases, 12.9%) and lung cancer (386,300 cases, 12.1%).

Prof Boyle said the rise in the number of breast cancer cases could be attributed partially to the introduction of organised mammography screening programmes, which meant that more cancers were detected, and at an earlier stage. "These programmes have the short-term consequence of increasing the incidence, which has risen by 16% since our latest 2004 estimates." Despite the benefit of screening programmes, he said that deaths from breast cancer were continuing to rise (130,000 in 2004, 131,900 in 2006) because of the ageing population.

In women, after breast cancer, colorectal cancer (195,400, 13.1% of the total) and cancer of the uterus (149,300, 10%) were the most commonly diagnosed cancers.

In men, the widespread use of the Prostate Specific Antigen (PSA) tests was also having an effect on the numbers of prostate cancers being detected; prostate cancer was the most frequent cancer diagnosed (345,900, 20.3% of the total), followed by lung cancer (292,200, 17.2%) and colorectal cancer (217,400, 12.8%).

Prof Boyle said: "Despite the widespread use of PSA testing in many European countries, the number of deaths from prostate cancer has increased by around 16% since 1995 due, in large measure, to the rapid increase in the numbers of men reaching older ages."

Screening programmes needed

The second most common cause of cancer death in both men and women was colorectal cancer. "There remains hope that dietary modifications, increased physical activity and avoidance of obesity could lead to reductions in the incidence and mortality from colorectal cancer," said Prof Boyle. "However, progress has been very slow; the number of deaths has increased by 1.8% since our previous 2004 estimates. Screening for colorectal cancer has been shown to be effective, and clearly there is a need for organised colorectal cancer screening programmes throughout Europe."

Deaths from stomach cancer are continuing to decline in men and women throughout Europe, although it still accounts for 5.6% of all new cases of cancer (5.9% in 2004) and 7.4% of all cancer deaths (8.1% in 2004). "However, higher incidence and mortality rates occur in the Central and Eastern European countries, possibly reflecting a lower level of affluence, a diet lower in fresh fruits and vegetables and higher rates of Helicobacter pylori infection," said Prof Boyle.

Significant differences in the chances of surviving other cancers existed between the Eastern and Baltic European countries and other European countries. In the 25 member countries of the European Union an estimated 23,600 women died from cancer of the uterus in 2006 and 46,600 died in the whole of Europe.. "The number of years of life lost could be reduced in women living in Central and Eastern European countries if efficient national cervical cancer screening programmes were in place," said Prof Boyle.

He concluded: "The increased burden of cancer incidence in Europe between 2004 and 2006, which is estimated to have risen by 300,000 to 3.2 million, demonstrates the impact of the ageing of the European population and underlines the need for active and effective tobacco control measures and screening programmes in Europe."

###

[1] Estimates of the cancer incidence and mortality in Europe in 2006. Annals of Oncology. doi:10.1093/annonc/mdl498 [2] In 2006 the European Union comprised: Austria, Belgium, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, The Netherlands and United Kingdom. Europe comprised the 25 EU countries plus Albania, Belarus, Bosnia Herzegovina, Bulgaria, Croatia, Iceland, Macedonia, Moldova, Norway, Romania, Russian Federation, Serbia and Montenegro, Switzerland, Ukraine.

Contact: Emma Mason
European Society for Medical Oncology

February 20, 2007

First Patients Undergo Surgery In Northwest Biotherapeutics' Phase II Brain Cancer Trial

Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBT.OB), a biotechnology company focused on cancer immunotherapy, today announced that the first two patients in its pivotal Phase II clinical trial have undergone surgery for newly diagnosed Glioblastoma multiforme (GBM), which is the first step in the preparation of the Company's DCVax(R)-Brain treatment. The surgeries took place at Henry Ford Hospital in Detroit, MI.

"We are very pleased to begin the patient accrual process for this Phase II trial, and anticipate completing enrollment in Q4 of this year. We are also working with nine other clinical sites to accelerate patient accrual during the next few months," stated Alton Boynton, President of Northwest Biotherapeutics. Dr. Boynton further stated, "I consider this a major milestone for NWBT and look forward to rapid patient accrual in this important clinical trial."

The DCVax(R)-Brain treatment consists of three initial immunizations at 2 week intervals, followed by four booster injections at 2- and 4-month intervals for the remainder of year one, and thereafter semi-annual maintenance injections for an additional two years. DCVax(R)-Brain showed no toxicity in previous studies in over 100 patients.

The DCVax(R)-Brain Phase II clinical trial is based on two Phase I studies carried out at UCLA under the direction of Linda Liau, M.D., Ph.D., Director of the Malignant Brain Tumor Program at the UCLA School of Medicine. Each of the trials included both newly diagnosed (early stage) GBM, and recurrent (late stage) GBM. DCVax(R)-Brain has doubled the time to progression and the overall survival time in both the early and the late stage patients. The data for those trials continue to mature.

In the newly diagnosed GBM patients, DCVax(R)-Brain has increased the time to recurrence or progression of disease as described in Kaplan Meier plots from 8.1 months with standard of care treatments to 18.1 months with DCVax(R)- Brain (p< 0.00001). Kaplan Meier plots also showed that DCVax(R)-Brain increased median overall survival from 17 months with standard of care treatments to 33.8 months (p=0.0044) for DCVax(R)-Brain treated patients. Ten of the 19 patients remain alive for periods ranging to date from 10 to 80 months. Similarly, in recurrent (late stage) patients, DCVax(R)-Brain has increased median survival from 6.4 months for historical controls receiving standard of care to 13.2 months for patients receiving DCVax(R)-Brain.

DCVax(R)-Brain uses a patient's own tumor, surgically removed as part of the standard of care, to prepare a mix of their personal cancer biomarkers. These personal cancer biomarkers are then loaded into the patient's own dendritic cells (the master cells responsible for starting and managing the body's overall immune response), and injected back into the patient through a simple intra-dermal injection, similar to an insulin shot, at various intervals over a three year period. The DCVax(R)-Brain Phase II trial is designed and powered as a pivotal trial, and will involve 141 patients. All patients will receive full standard of care treatment, which includes surgery, radiation and chemotherapy, and approximately 94 of these patients will also receive DCVax(R)-Brain. A sufficient quantity of each patient's personal therapeutic cancer vaccine is prepared in a single manufacturing procedure to provide for 3 years of treatment.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines, and therapeutic antibodies. The Company's three lead product candidates are:

DCVax(R)-Brain, a personalized dendritic cell vaccine for treatment of Glioblastoma multiforme, which has entered into a large Phase II pivotal clinical trial cleared by the FDA;

DCVax(R)-Prostate, a personalized dendritic cell vaccine for treatment of hormone independent non-metastatic prostate cancer, which is ready to enter a Phase III clinical trial cleared by the FDA; and

Monoclonal antibodies to CXCR4, which are in late pre-clinical development for the treatment of multiple cancers. For further information, please visit the company web site at http://www.nwbio.com/.

The Company also has a robust pipeline of additional products cleared by FDA for early stage clinical trials in multiple other cancers.

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the company's ability to raise additional capital, risks related to the company's ability to enroll patients in its Phase II clinical trial of DCVax(R)-Brain and complete the trial on a timely basis, the uncertainty of the clinical trials process, the timely performance of third parties, and whether DCVax(R)-Brain will demonstrate safety and efficacy and the timely performance of third parties. Additional information on these and other factors, which could affect the company's results, is included in its Securities and Exchange Commission ("SEC") filings. Finally, there may be other factors not mentioned above or included in the company's SEC filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

Northwest Biotherapeutics, Inc.
http://www.nwbio.com/

February 19, 2007

Benign Or Malignant? MTOR Makes The Decision

Tuberous sclerosis complex (TSC) is a genetic disorder that results in sufferers developing benign tumors in many parts of their body. It is caused by genetic mutation of either of two genes, TSC1 or TSC2. The proteins encoded by these genes are negative regulators of a signaling pathway that is initiated at the cell surface by a ligand binding to PDGFR and that involves activation of PI3K, AKT, and mTOR. The fact that individuals with TSC develop only benign tumors is somewhat surprising because genetic mutations that cause increased PDGFR, PI3K, and AKT activity are associated with malignant cancer, as are inactivating genetic mutations of other negative regulators of this signaling pathways (including PTEN). In a study appearing online in advance of publication in the March print issue of the Journal of Clinical Investigation, researchers from the Chinese Academy of Medical Sciences and Peking Union Medical College, People's Republic of China, use mouse models of TSC to provide a potential explanation for the fact that individuals with TSC develop only benign tumors.

The lack of malignant tumors in mice expressing decreased levels of TSC1 or TSC2 is associated with decreased PDGFR expression and decreased PI3K and AKT activity, despite increased mTOR activity. Hongbing Zhang and colleagues now show that in mouse cell lines, activation of PI3K or AKT, as well as inhibition of PTEN, results in decreased PDGFR expression and negative feedback to dampen AKT activity, despite increased mTOR activity. Furthermore, inhibiting mTOR restored PDGFR expression levels and AKT activity in mouse cell lines expressing decreased levels of TSC1 or TSC2, and overexpression of active AKT or PDGFR in such cells rendered them able to induce malignant tumors when transplanted into immunocompromised mice. This study therefore demonstrates that increased mTOR activity decreases PDGFR expression and AKT activity in mouse cells expressing decreased levels of TSC1 or TSC2. More importantly, it offers a potential explanation for the observation that humans expressing mutant forms of TSC1 or TSC2 develop only benign tumors.

TITLE: PDGFRs are critical for PI3/Akt activation and negatively regulated by mTOR

AUTHOR CONTACT:
Hongbing Zhang
Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.

###

JCI table of contents -- February 8, 2006

Contact: Karen Honey
Journal of Clinical Investigation

Anita Roddick Has Hepatitis C

Dame Anita Roddick, the 64-year old British environmental campaigner and founder of Body Shop revealed today that she has Hepatitis C.

"I have Hepatitis C - it's a bit of a bummer but you groan and move on," she says on her website.

According to Dame Anita, she contracted the disease when she received a blood transfusion in 1971 when her daughter Sam was born. However, it was only when she had a blood test recently that the discovery was made. She also has cirrhosis of the liver, one of the long term effects of the disease.

Dame Anita lost no time in adding her voice to the campaign to raise awareness of Hepatitis C and to stimulate more government action and funding. She has just become Patron of the UK's Hepatitis C Trust, a charity set up in 2001 by a group of people who have the disease.

Hepatitis C is a virus that passes from person to person mostly through infected blood. This was the most common route in the UK until 1991 when donated blood began to be screened for the virus.

The virus causes inflammation of the liver (that is literally what "hepatitis" means), and over time begins to limit the important function the liver plays in keeping the body healthy. More recent research has revealed that Hepatitis C also causes damage to other parts of the body, such as the digestive system, the immune system, the brain and the lymphatic system.

Hepatitis C used to be called non-A non-B hepatitis (NANBH) when in the 1980s scientists realised that something like Hepatitis A and Hepatitis B was causing liver damage. It was not until 1989 that they began calling it Hepatitis C, and shortly afterwards a blood screening test for was developed.

The virus is based on RNA which means that it mutates much faster than viruses based on DNA and this makes it hard for the immune system to develop the antibodies that can seek out and destroy the new mutations.

Hepatitis C infections have two stages: acute infection which is the first 6 months after initial infection, and chronic infection. During the acute phase very few symptoms are present, and about 20 per cent of people who become infected manage to shed the virus and do not go on to have chronic infection.

But for the remaining 80 per cent of people who become infected the chronic stage sets in for decades and that's when the serious damage is done. It can take decades for long term effects to show, or symptoms can show almost immediately.

The long term effects of Hepatitis C lead to liver fibrosis and cirrhosis (where the liver becomes scarred), cancer, and liver disease, the latter often requiring a transplant. The timescale in which these things may happen appear to be erratic and bear no relation to symptom severity. Some people can go undiagnosed for years, feel OK, and then find out they have severe fibrosis and cirrhosis.

This is why it can be decades, as in the case of Dame Anita, before people discover they have what has become known as "the silent killer". Diagnosis is also compromised because other symptoms like fatigue, depression, insomnia, tummy pains and upsets, skin irritations and rashes, are mostly put down to other causes.

It is estimated that some 200 million people all over the world have Hepatitis C, with some countries like Egypt having a high prevalence of around 10 per cent of the population, while in Northern Europe the figure is much lower at 1 per cent.

According to Dame Anita, it is very important for people to find out if they have the disease, which the Hepatitis C Trust estimates to be about half a million people in the UK, most of whom have no idea they are infected. Although there is no cure, care and treatments for the symptoms do exist, and "everyone with hep C deserves proper care and treatment if they want it," she says.

"It's especially important that people like me, who are over fifty and who had blood a transfusion before 1991, come forward for testing," says Dame Anita, who stresses there is also a priority in terms of stopping the transmission of Hepatitis C, in raising awareness and overcoming the stigma that surrounds it, which like the case of HIV, "stops people getting a fair deal."

Click here for Hepatitis C Trust (UK)

Written by: Catharine Paddock
Writer: Medical News Today

Tumors' Genetic Profile Captured By Technology

A study led by researchers at Dana-Farber Cancer Institute and Broad Institute of the Massachusetts Institute of Technology and Harvard University provides the first demonstration of a practical method of screening tumors for cancer-related gene abnormalities that might be treated with "targeted" drugs.

The findings, published online on the Nature Genetics Web site, may help relieve a bottleneck between scientists' expanding knowledge of the genetic mutations associated with cancer and the still nascent ability of doctors to use that knowledge to benefit patients. The results constitute an important step toward the era of "personalized medicine," in which cancer therapy will be guided by the particular set of genetic mutations within each patient's tumor, the authors suggest.

"It's universally recognized that cancer is a disease of the genome, of mutations within genes responsible for cell growth and survival, and a great deal of effort has gone into finding those mutations, to the point where several hundred to a thousand are now known," said the study's senior author, Levi Garraway, MD, PhD, of Dana-Farber and the Broad Institute. "The challenge has been how to determine which of them are involved in each of the hundreds of kinds of cancer that occur in humans -- and to develop accurate, affordable methods of detecting key mutations in tumor samples. This study suggests that such a method is feasible on a large scale."

The authors took advantage of a scientific serendipity to devise a simple test to detect important cancer mutations. Mutations in oncogenes (genes linked to cancer) do not occur randomly; rather, they seem to arise most frequently in certain regions of the oncogenes. As a result, researchers didn't necessarily have to scan the entire length of each gene, but could focus instead on the sections most likely to harbor mutations.

They performed these screenings with a technology known as high-throughput genotyping, a fast, relatively inexpensive way of profiling gene mutations within cells. It involves extracting DNA from a tumor sample, copying this material thousands of times, depositing segments of it in tiny "wells" on a small plate, and mixing in reagents that reveal whether each segment carries a specific mutation. Automated equipment then reads the plates to determine which mutations are present in each sample.

In the study, the researchers scanned 1,000 human tumor samples for 238 known mutations in 17 specific oncogenes. (Those 17 were chosen because they are mostly "classic, well-known" contributors to cancer, Garraway stated.) They found at least one mutation in 298 of the samples, or 30 percent of the entire group, which was in keeping with the rates reported in scientific literature for the types of cancer examined.

"Mutations were identified in the percentages we expected," Garraway said, "which indicates this technique is on-target for the mutations we were interested in. Overall, the technique worked very well: we were able to obtain mutation profiles that were accurate, sensitive, and cost-effective." The cost of processing each sample was between $50 and $100, although the figure would probably be somewhat higher if the technology were used in cancer clinics to test for large numbers of oncogene mutations.

The scans produced some surprises as well. Mutations were found in several types of tumors where they had not been previously recognized. Researchers also discovered an unexpectedly large number of instances where the same set of mutations co-occurred within tumor cells, suggesting that oncogenes often work in partnership.

As promising as high-throughput genotyping is for cancer treatment and research, its capacity will need to be expanded so it can handle larger numbers of mutations. The next step, Garraway explained, would be to work with clinical investigators to explore whether use of the technology is feasible in a clinical setting and whether it actually improves doctors' ability to classify and treat individual tumors.

"We've shown the practical potential of this technique," observed Garraway, who is also an instructor in medicine at Harvard Medical School. "It is a step toward the day when cancer patients will routinely have their tumors scanned for specific mutations, and treatment will be based on the cancer's particular genetic profile."

###

Major funding for the study was provided by grants from Genentech, Inc., the American Cancer Society, the National Cancer Institute, the Prostate Cancer Foundation, the Burroughs-Wellcome Fund, the Robert Wood Johnson Foundation, and the Novartis Institute for Biomedical Research.

The co-lead authors of the paper are Roman Thomas, MD, formerly of Dana-Farber and the Broad Institute, and Alissa Baker of Dana-Farber, who contacted cancer researchers around the world to obtain the 1,000 tumor samples used in the study. Co-authors include Matthew Meyerson, MD, PhD, also of Dana-Farber and the Broad Institute, and researchers from Dana-Farber; the University of Texas Southwestern Medical Center; Nagoya City University Medical School, in Nagoya, Japan; the David Geffen School of Medicine at the University of California at Los Angeles; Brigham and Women's Hospital; University Hospital of Zurich, Switzerland; Northwestern University Feinberg School of Medicine; the National Cancer Institute; National Naval Medical Center; the Medical University of Vienna, Austria; the Center of Molecular Medicine at the Austrian Academy of Sciences; the Wistar Institute in Philadelphia; the Navartis Institutes for Biomedical Research; Harvard Medical School; the Max-Planck Institute for Neurological Research in Cologne, Germany; and the University of Cologne.

Dana-Farber Cancer Institute (http://www.dana-farber.org/) is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute.

Contact: Robbin Ray
Dana-Farber Cancer Institute

Genta Cites Publication Of Study Showing Improved Outcomes In CLL Patients Treated With Genasense(R) Plus Chemotherapy

Genta Incorporated (Nasdaq: GNTA) today announced the publication of findings from a Phase 3 trial of the Company's lead anticancer drug, Genasense(R) (oblimersen sodium) Injection, when used in combination with chemotherapy for treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL). The findings were published on-line this week in the Journal of Clinical Oncology, ahead of its tentatively scheduled print publication date of March 20, 2007.

Conducted at 100 centers in the U.S., Europe, Canada, Australia and South America, patients with relapsed or refractory CLL received fludarabine plus cyclophosphamide (Flu/Cy) chemotherapy with or without Genasense. This trial -- the first randomized study ever conducted in this population -- achieved its primary endpoint, which was a statistically significant increase in the proportion of patients who achieved a complete or nodular partial response (CR/nPR) (17% vs. 7%; P=0.025).

Patients who achieved CR/nPR experienced the disappearance of all predefined CLL symptoms, including fever, night sweats, fatigue, abdominal discomfort due to an enlarged spleen, and impaired mobility due to swollen lymph nodes.

The key secondary endpoint -- duration of CR/nPR -- was also significantly longer for patients treated with Genasense (median = not reached but will exceed 36+ months in the Genasense group vs. 22 months for patients treated with chemotherapy alone).

Among patients who achieved a CR/nPR with Genasense, 70 percent were alive at three years versus 38 percent for the control arm. Among patients who achieved a partial response, 45 percent who received Genasense were alive at three years compared to 33 percent for the control arm.

The lead and senior authors of the article are, respectively, Dr. Susan O'Brien, Professor of Medicine, Department of Leukemia, M.D. Anderson Cancer Center, and Dr. Kanti R. Rai, Chief, Hematology and Oncology, North Shore/Long Island Jewish Medical Center, and Professor of Medicine, Albert Einstein College of Medicine. An abstract of this article that addresses safety and efficacy in the trial can be accessed at: http://www.jco.org/cgi/content/abstract/JCO.2006.07.1191v1.

About Genasense

Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company's research platform is anchored by two major programs that center on oligonucleotides (RNA- and DNA- based medicines) and small molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its oligonucleotide program. Genta has completed a pending Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment of patients with advanced melanoma. The leading drug in Genta's small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. For more information about Genta, please visit our website at: http://www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward-looking statements include, without limitation, statements about: the Company's ability to obtain necessary regulatory approval for Genasense(R) from the U.S. Food and Drug Administration ("FDA") or European Medicines Agency ("EMEA");

-- the safety and efficacy of the Company's products or product candidates;

-- the Company's assessment of its clinical trials;

-- the commencement and completion of clinical trials;

-- the Company's ability to develop, manufacture, license and sell its products or product candidates;

-- the Company's ability to enter into and successfully execute license and collaborative agreements, if any;

-- the adequacy of the Company's capital resources and cash flow projections, and the Company's ability to obtain sufficient financing to maintain the Company's planned operations;

-- the adequacy of the Company's patents and proprietary rights;

-- the impact of litigation that has been brought against the Company and its officers and directors and any proposed settlement of such litigation;

-- the Company's ability to regain compliance with the NASDAQ's listing qualifications; and

-- the other risks described under Certain Risks and Uncertainties Related to the Company's Business, as contained in the Company's Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2005 and its most recent quarterly report on Form 10-Q.

Genta Incorporated
http://www.genta.com

States, France Take Actions On HPV Vaccination

About two dozen states are "struggling to decide" how to recommend girls ages 11 and 12 receive an HPV vaccine, the Chicago Tribune reports. One option would be to provide state funding to pay for vaccines or force insurance carriers to do so, and the second option would be to add the HPV vaccine to the list of mandatory vaccinations for admission to school (Peres/Japsen, Chicago Tribune, 2/11). Merck's HPV vaccine Gardasil and GlaxoSmithKline's HPV vaccine Cervarix in clinical trials have been shown to be 100% effective in preventing infection with HPV strains 16 and 18, which together cause about 70% of cervical cancer cases. FDA in July 2006 approved Gardasil for sale and marketing to girls and women ages nine to 26, and CDC's Advisory Committee on Immunization Practices later that month voted unanimously to recommend that girls ages 11 and 12 receive the vaccine. GSK in April plans to file for FDA approval of Cervarix, and it expects approval by the end of this year (Kaiser Daily Women's Health Policy Report, 2/8). Merck has "fanned out" across the U.S. to urge states to either mandate HPV vaccines for young girls or to spend millions of dollars of public funds to purchase the vaccine for use in health clinics, the Washington Post reports. The company also has launched a television advertising campaign about HPV, cervical cancer and Gardasil. "We're certainly very proud of our efforts," Margaret McGlynn, president of Merck's vaccines division, said, adding, "We spent over 10 years developing Gardasil. We think this is a very important advance in women's health" (Gardner, Washington Post, 2/11). France and several states recently have taken actions on HPV vaccination. Summaries appear below.

California: A bill (AB 16) that would require all California girls entering the sixth grade to receive an HPV vaccine, with an exception for girls whose parents file a letter stating that participation is against their beliefs, has some parents "decrying" what they believe to be an "incursion on parental rights," the Los Angeles Times reports. Gov. Arnold Schwarzenegger (R) has not taken a public stand on the bill, but his proposed fiscal year budget for 2007 includes about $11 million in additional funding to cover the vaccination for 50,000 Medi-Cal beneficiaries ages 19 to 26 (Uribarri, Los Angeles Times, 2/12).
New York: State Assembly member Amy Paulin (D) plans to introduce a measure this week that will mandate the HPV vaccine to girls ages 11 and 12, Long Island Newsday reports. Christine Anderson, spokesperson for Gov. Eliot Spitzer (D), said whether the HPV vaccine "will be mandated is something that will be looked at" by the governor, adding that $1.5 million has been included in the executive budget "to promote and expand access to the vaccine" for low-income women and girls. If the budget is approved, the funds would provide the vaccine to an estimated 4,000 women and girls annually (Ricks, Long Island Newsday, 2/11).
Vermont: Rep. Denise Barnard (D) recently introduced a bill (H 256) that would require girls entering the sixth grade to receive an HPV vaccine, the Barre-Montpelier Times Argus reports (Larkin, Barre-Montpelier Times Argus, 2/11). The measure would allow girls to opt out of the requirement if their parent or guardian submits in writing that the "person, parent or guardian has religious beliefs or moral convictions opposed to immunization" and has received information about the vaccine and the link between HPV and cervical cancer (H 256 text, 2/12).

Editorials

Chicago Tribune: FDA approval of Gardasil has "ripped open a riveting debate about how far lawmakers should go to protect us from ourselves" a Tribune editorial says. As "emotions hea[t] up, a lot of misinformation and unnecessary anxieties are being stirred," the editorial says, adding, "For now, Gardasil appears to be a very important and welcome life-saving step in the fight against cancer" (Chicago Tribune, 2/11).
Washington Post: The debate over requiring girls to be vaccinated "should be about what's in the best interests of ... young women" and should "not be about the interests of the maker of the vaccine," a Post editorial says. According the editorial "the two are being confused" because of Merck's lobbying campaign. "The best move Merck can now make is to back off," the Post says (Washington Post, 2/11).

France
Health Minister Xavier Bertrand on Friday announced that France will subsidize the cost of Gardasil during the first half of 2007, Reuters reports. It is a "major step towards improving the health of the public," Bertrand said, adding, "We have already got the process under way, and before the end of the first half of 2007, before July, it will be subsidized" (Reuters, 2/9).

"Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

Oncology

Cancer Topics

Medical Blogs

April 15, 2007

Call For Better Prostate Cancer Biopsies

March 7, 2007

Call For Better Prostate Cancer Biopsies

March 5, 2007

Dendreon's PROVENGE Granted FDA Priority Review For The Treatment Of Asymptomatic, Metastatic, Androgen-Independent Prostate Cancer

March 4, 2007

Panacea Pharmaceuticals Initiates Pivotal, Prospective Multi-Center Study To Evaluate The Diagnostic Performance Of PC Detect(SM) For Prostate Cancer

US Cancer Deaths Fall Second Year In A Row Despite Growing And Aging Population

Sunshine Pill For Prostate Cancer In 2009?

M. D. Anderson Announces Collaboration With The National Cancer Institute Of Mexico

March 2, 2007

Ciphergen Announces Issuance Of European Patent Covering A Method For Aiding Prostate Cancer Diagnosis

National Prostate Cancer Coalition Launches Clinical Trial Education Program

Swedish Cancer Institute First In The World To Offer GPS For The Body(R) To Assist With Precision-Guided Prostate Cancer Treatments

February 26, 2007

Europe's Aging Population Causing Major Increase In Cancer Burden Experts Warn

February 20, 2007

First Patients Undergo Surgery In Northwest Biotherapeutics' Phase II Brain Cancer Trial

February 19, 2007

Benign Or Malignant? MTOR Makes The Decision

Anita Roddick Has Hepatitis C

Tumors' Genetic Profile Captured By Technology

Genta Cites Publication Of Study Showing Improved Outcomes In CLL Patients Treated With Genasense(R) Plus Chemotherapy

States, France Take Actions On HPV Vaccination

Search For Health

Blog Archive